SHENYANG, China, Jan. 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Kevin Teo to the position of Chief Financial Officer effective January 28, 2008. Mr. Teo will replace Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008.
Dr. Jing Lou, CEO of 3SBio, commented, "I am pleased to welcome Kevin Teo to 3SBio's senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin's ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors."
Mr. Teo, 42, brings to 3SBio over 20 years of relevant experience,
having held a number of senior finance and accounting positions in the
energy and technology industries throughout Asia. Most recently, he served
as Group Business Controller at East Asia Power (Xiamen), where he oversaw
and managed finance
|SOURCE 3SBio Inc.|
Copyright©2008 PR Newswire.
All rights reserved